Establishment of a high-risk medication list and preventive and therapeutic measures for drug-induced hypofibrinogenemia based on the Delphi method

WEN Xiao; CAI Le; LIU Ning; GAO Ao; ZHU Man

doi:10.6039/j.issn.1001-0408.2026.07.04

您当前的位置：

首页 >

文章列表页 >

Establishment of a high-risk medication list and preventive and therapeutic measures for drug-induced hypofibrinogenemia based on the Delphi method

更新时间：2026-07-16

- Establishment of a high-risk medication list and preventive and therapeutic measures for drug-induced hypofibrinogenemia based on the Delphi method
- ZHONGGUO YAOFANG Vol. 37, Issue 7, Pages: 848-853(2026)
- 作者机构：
  
  1.中国人民解放军总医院医疗保障中心药剂科，北京　100853
  2.蚌埠医科大学药学院，安徽蚌埠　233030
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.07.04
  CLC： R95;R969.3
- Received：07 November 2025，
  
  Revised：2026-03-09，
  
  Accepted：09 March 2026，
  
  Published：15 April 2026
- 稿件说明：
移动端阅览
文笑,蔡乐,刘宁,等.基于德尔菲法的药源性低纤维蛋白原血症的高风险药品目录构建及防治策略 [J].中国药房,2026,37(07):848-853.

WEN Xiao,CAI Le,LIU Ning,et al.Establishment of a high-risk medication list and preventive and therapeutic measures for drug-induced hypofibrinogenemia based on the Delphi method[J].ZHONGGUO YAOFANG,2026,37(07):848-853.
文笑,蔡乐,刘宁,等.基于德尔菲法的药源性低纤维蛋白原血症的高风险药品目录构建及防治策略 [J].中国药房,2026,37(07):848-853. DOI： 10.6039/j.issn.1001-0408.2026.07.04.

WEN Xiao,CAI Le,LIU Ning,et al.Establishment of a high-risk medication list and preventive and therapeutic measures for drug-induced hypofibrinogenemia based on the Delphi method[J].ZHONGGUO YAOFANG,2026,37(07):848-853. DOI： 10.6039/j.issn.1001-0408.2026.07.04.

摘要

目的

建立药源性低纤维蛋白原血症高风险药品目录及防治策略，为该疾病的防治提供参考。

方法

整合国内外病例报道、回顾性病例对照研究、药品不良反应自发报告数据库，筛选出19种在国内上市的药源性低纤维蛋白原血症高风险药品；围绕上述药品的临床特征与作用机制，系统梳理相关风险因素，并总结现有治疗方案，据此初步拟定防治策略建议。以指标重要性评分均值≥3.5分及变异系数＜0.3为筛选指标，通过两轮德尔菲法函询，对拟定条目进行论证、修订并最终达成共识。

结果

两轮专家咨询的权威程度均为0.904，第一轮函询中药源性低纤维蛋白原血症高风险药品目录、防治策略的Kendall协调系数（Kendall’

）分别为0.390和0.223，

均小于0.05；第二轮函询中上述2个条目的Kendall’

分别为0.227和0.200，

均小于0.05。经两轮专家咨询论证，最终确定了以血凝酶、部分抗感染药物为代表的11种药源性低纤维蛋白原血症高风险药品，以及贯穿“用药前评估-用药中监测-出血事件处理”全过程的5条防治策略。

结论

本研究建立了科学、可靠的药源性低纤维蛋白原血症高风险药品目录及防治策略，可为该疾病的早期识别、分层管理与精准干预提供理论依据与实践支撑。

Abstract

OBJECTIVE

To establish a high-risk medication list and preventive and therapeutic measures for drug-induced hypofibrinogenemia， and to provide a reference for the prevention and treatment of this condition.

METHODS

By integrating domestic and international case reports， retrospective case-control studies， and spontaneous adverse drug reaction reporting databases， 19 domestically marketed high-risk drugs for drug-induced hypofibrinogenemia were identified. Based on the clinical characteristics and mechanisms of these drugs， relevant risk factors were systematically reviewed， and existing treatment options were summarized， leading to the preliminary development of recommended preventive and therapeutic measures. A two-round Delphi consultation was conducted to evaluate， revise， and ultimately reach consensus on the preliminary findings， using a mean importance score of ≥3.5 points for indicators and a coefficient of variation ＜0.3 as screening criteria.

RESULTS

The coefficient of expert authority for both rounds of expert consultation was 0.904. In the first round， the Kendall coordination coefficients （Kendall’s

） for the high-risk medication list and the proposed preventive and therapeutic measures were 0.390 and 0.223 （

＜0.05）， respectively. In the second round， the Kendall’s

were 0.227 and 0.200 （

＜0.05）， respectively. After two rounds of expert consultation and discussion， 11 high-risk drugs for drug-induced hypofibrinogenemia， represented by hemocoagulase and certain anti-infective agents， were ultimately identified， along with 5 preventive and therapeutic measures spanning the entire process of “pre-medication assessment， intra-medication monitoring， and bleeding event management”.

CONCLUSIONS

This study has established a scientific and reliable high-risk medication list， and corresponding preventive and therapeutic measures for drug-induced hypofibrinogenemia， providing a theoretical basis and practical support for the early identification， stratified management， and precise intervention of this condition.

关键词

Keywords

references

TIEDE A ， ZIEGER B ， LISMAN T . Acquired bleeding disorders [J ] . Haemophilia ， 2021 ， 27 （ S3 ）： 5 - 13 .

ZHANG Q ， WANG J E ， LIU H ， et al . Risk factors for tigecycline-induced hypofibrinogenaemia [J ] . J Clin Pharm Ther ， 2020 ， 45 （ 6 ）： 1434 - 1441 .

MA W M ， ZHAO T ， YU L H ， et al . Incidence，clinical features，and risk factors of hemocoagulase-induced hypofibrinogenemia：a retrospective real-world study [J ] . Medicine ， 2024 ， 103 （ 15 ）： e37773 .

AN Q ， MA R L ， YUAN D W ， et al . Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia [J ] . Clin Rheumatol ， 2024 ， 43 （ 5 ）： 1491 - 1501 .

HUANG X Y ， MORETON F C ， KALLADKA D ， et al . Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke [J ] . Stroke ， 2015 ， 46 （ 12 ）： 3543 - 3546 .

高奥，蔡乐，朱曼，等 . 药源性低纤维蛋白原血症自发报告分析及数据挖掘 [J ] . 临床药物治疗杂志， 2024 ， 22 （ 12 ）： 22 - 27 .

WEN X ， CAI L ， GAO A ， et al . Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System [J ] . Int J Clin Pharm ， 2025 ， 47 （ 3 ）： 755 - 766 .

蔡乐，张慕雪，文笑，等 . 住院患者药源性低纤维蛋白原血症主动监测研究 [J ] . 临床药物治疗杂志， 2025 ， 23 （ 9 ）： 64 - 70 .

文笑，蔡乐，高奥，等 . 药源性低纤维蛋白原血症临床特征及危险因素的文献分析 [J ] . 中国药房， 2025 ， 36 （ 13 ）： 1648 - 1654 .

MA C Q ， REN X L ， PANG N ， et al . Incidence，characteristics，and risk factors of hypofibrinogenemia induced by generic tigecycline：a retrospective study [J ] . Naunyn Schmiedebergs Arch Pharmacol ， 2025 ， 398 （ 3 ）： 2717 - 2727 .

CAI L ， WEN X ， QIU Z H ， et al . Characteristics，risk factors and a risk prediction model of tocilizumab-induced hypofibrinogenemia：a retrospective real-world study of inpatients [J ] . BMC Pharmacol Toxicol ， 2025 ， 26 （ 1 ）： 5 .

董慧秋，汤少梁 . 集采常态化背景下仿制药质量安全应急管理能力评估指标体系构建 [J ] . 中国药房， 2024 ， 35 （ 13 ）： 1545 - 1551 .

吴玥，沈秉正，张帆，等 . 直接口服抗凝药用于肿瘤相关静脉血栓预防的临床综合评价体系研究 [J ] . 中国药房， 2025 ， 36 （ 11 ）： 1384 - 1388 .

KATTULA S ， BYRNES J R ， WOLBERG A S . Fibrinogen and fibrin in hemostasis and thrombosis [J ] . Arterioscler Thromb Vasc Biol ， 2017 ， 37 （ 3 ）： e13 - e21 .

WOODS A ， BRULL D J ， HUMPHRIES S E ， et al . Gene- tics of inflammation and risk of coronary artery disease：the central role of interleukin-6 [J ] . Eur Heart J ， 2000 ， 21 （ 19 ）： 1574 - 1583 .

SALVATORE C M ， TECHASAENSIRI C ， TAGLIABUE C ， et al . Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia [J ] . Antimicrob Agents Chemother ， 2009 ， 53 （ 4 ）： 1546 - 1551 .

SHI X P ， ZUO C C ， YU L L ， et al . Real-world data of tigecycline-associated drug-induced liver injury among patients in China：a 3-year retrospective study as assessed by the updated RUCAM [J ] . Front Pharmacol ， 2021 ， 12 ： 761167 .

JIANG T T ， HUANG X H ， LIU Q H ， et al . Risk factors for tigecycline-associated hepatotoxicity in patients in the intensive care units of 2 tertiary hospitals：a retrospective study [J ] . J Clin Pharmacol ， 2022 ， 62 （ 11 ）： 1426 - 1434 .

BRANDTNER A ， BACHLER M ， FRIES D ， et al . Tigecycline interferes with fibrinogen polymerization independent of peripheral interactions with the coagulation system [J ] . Antibiotics ， 2020 ， 9 （ 2 ）： 84 .

ZHANG Q ， ZHOU S M ， ZHOU J . Tigecycline treatment causes a decrease in fibrinogen levels [J ] . Antimicrob Agents Chemother ， 2015 ， 59 （ 3 ）： 1650 - 1655 .

WU X Q ， ZHAO P ， DONG L ， et al . A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia [J ] . Medicine ， 2017 ， 96 （ 49 ）： e9124 .

KARAKAYALı B ， ONSAL OZTURK D ， YAZAR A S ， et al . Hypofibrinogenemia and intra-articular hemorrhage due to valproic acid [J ] . Pediatr Int ， 2016 ， 58 （ 12 ）： 1358 - 1359 .

FRANCHINI M ， LIPPI G . Fibrinogen replacement therapy：a critical review of the literature [J ] . Blood Transfus ， 2012 ， 10 （ 1 ）： 23 - 27 .

DANÉS A F ， CUENCA L G ， BUENO S R ， et al . Efficacy and tolerability of human fibrinogen concentrate admini- stration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding [J ] . Vox Sang ， 2008 ， 94 （ 3 ）： 221 - 226 .

FENGER-ERIKSEN C ， LINDBERG-LARSEN M ， CHRISTENSEN A Q ， et al . Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations [J ] . Br J Anaesth ， 2008 ， 101 （ 6 ）： 769 - 773 .

LENG B ， SHEN C W ， GAO T T ， et al . Incidence，characteristics and risk factors of hypofibrinogenemia associated with tigecycline：a multicenter retrospective study in China [J ] . Front Pharmacol ， 2022 ， 13 ： 943674 .

BUZZATTI E ， FORGHIERI F ， PATERNO G ， et al . In BCR-ABL1 positive B-cell acute lymphoblastic leukemia，steroid therapy induces hypofibrinogenemia [J ] . J Clin Med ， 2022 ， 11 （ 7 ）： 1776 .

LEE J K ， YOON C S ， NA Y O ， et al . Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis [J ] . J Thorac Dis ， 2023 ， 15 （ 1 ）： 65 - 76 .

LI M X ， HE J ， DONG G Q ， et al . Serum concentration threshold and risk factors of tigecycline-induced hypofibrinogenaemia in critically ill patients [J ] . J Antimicrob Chemother ， 2025 ， 80 （ 1 ）： 200 - 208 .

段蓉，李正翔 . 基于德尔菲法和层次分析法构建《药品临床综合评价主题遴选指南》研究问题及主题遴选评估指标体系 [J ] . 中国药房， 2025 ， 36 （ 7 ）： 789 - 793 .

Views

132

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction and application of clinical inapplicability evaluation system for instructions of oral Chinese patent medicines containing toxic decoction pieces

Construction and evaluation of the performance management system for pharmacy practice based on the balanced scorecard

Construction of hospital preparation cost item library based on the Delphi method

Analysis of risk factors and construction of risk prediction model for batroxobin-related severe hypofibrinogenemia

Construction and application of the standardized management index system for traditional Chinese medicine reserved in the department of medical institutions

Related Author

TANG He

TANG Longlong

JU Xiaoyu

TANG Youquan

WANG Zhihua

CHENG Jie

LUO Xia

LUO Yuyan

Related Institution

Dept. of Pharmacy， Hebei Provincial Hospital of TCM

Dept. of Equipment， Hebei Provincial Hospital of TCM

Dept. of Critical Care Medicine， Xingtai General Hospital of North China Healthcare Group

Dept. of Pharmacy， Maternal and Child Health Hospital of Inner Mongolia Autonomous Region

Dept. of Pharmacy， the Third Affiliated Hospital of Sun Yat-sen University

⁰